Eliot L Gardner
Overview
Explore the profile of Eliot L Gardner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
3458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharafshah A, Lewandrowski K, Gold M, Fuehrlein B, Ashford J, Thanos P, et al.
Curr Neuropharmacol
. 2025 Jan;
PMID: 39865816
Introduction: Glucagon-Like Peptide-1 Receptor (GLP1R) agonists have become widespread anti-obesity/diabetes pharmaceuticals in the United States. Aim: This article aimed to provide our current knowledge on the plausible mechanisms linked to...
2.
Schneider P, Goldbaum D, Agarwal A, Taylor A, Sundberg P, Gardner E, et al.
Pharmacol Biochem Behav
. 2024 Dec;
247:173931.
PMID: 39626795
While stress increases vulnerability to development of addiction, the recruitment of corticotropin releasing factor (CRF) with excessive drug use heightens the risk of stress-induced relapse. CRF signaling is transmitted via...
3.
Galaj E, Barrera E, Persaud K, Nisanov R, Vashisht A, Goldberg H, et al.
Int J Neuropsychopharmacol
. 2023 Oct;
26(12):828-839.
PMID: 37864842
Background: There is a strong link between chronic stress and vulnerability to drug abuse and addiction. Corticotropin releasing factor (CRF) is central to the stress response that contributes to continuation...
4.
Froimowitz M, Taboada R, Poulos Z, Rainone D, Imler G, Gardner E, et al.
ACS Omega
. 2023 Oct;
8(39):35738-35745.
PMID: 37810691
An improved synthesis was developed for CDTP-32476, a potent slow-onset dopamine reuptake blocker that may have utility as a treatment for cocaine abuse. The enantiomers of the compound were separated...
5.
He Y, Madeo G, Liang Y, Zhang C, Hempel B, Liu X, et al.
Sci Adv
. 2022 Sep;
8(35):eabo1440.
PMID: 36054363
Physical exercise is rewarding and protective against drug abuse and addiction. However, the neural mechanisms underlying these actions remain unclear. Here, we report that long-term wheel-running produced a more robust...
6.
Galaj E, Hempel B, Moore A, Klein B, Bi G, Gardner E, et al.
Transl Psychiatry
. 2022 Jul;
12(1):286.
PMID: 35851573
Cannabinoid CB1 receptors (CB1Rs) have been major targets in medication development for the treatment of substance use disorders. However, clinical trials with rimonabant, a CB1R antagonist/inverse agonist, failed due to...
7.
Yang H, Hempel B, Bi G, He Y, Zhang H, Gardner E, et al.
J Neurosci
. 2022 Jan;
42(11):2327-2343.
PMID: 35091501
It is well established that glutamate plays an important role in drug-induced and cue-induced reinstatement of drug seeking. However, the role of glutamate in drug reward is unclear. In this...
8.
You Z, Gardner E, Galaj E, Moore A, Buck T, Jordan C, et al.
Mol Psychiatry
. 2022 Jan;
27(4):2171-2181.
PMID: 35064236
Ghrelin, an orexigenic hormone, has emerged as a critical biological substrate implicated in drug reward. However, the response of the ghrelin system to opioid-motivated behaviors and the role of ghrelin...
9.
You Z, Galaj E, Alen F, Wang B, Bi G, Moore A, et al.
Neuropsychopharmacology
. 2021 Dec;
47(8):1449-1460.
PMID: 34923576
Cocaine addiction is a significant medical and public concern. Despite decades of research effort, development of pharmacotherapy for cocaine use disorder remains largely unsuccessful. This may be partially due to...
10.
He X, Galaj E, Bi G, He Y, Hempel B, Wang Y, et al.
Front Pharmacol
. 2021 Sep;
12:722476.
PMID: 34566647
Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction. However, it is unclear whether β-caryophyllene (BCP), a natural product with a CB2 receptor agonist...